Effect Of Sglt2 Inhibitors On Hypretension, In Diabetic And Non-Diabetic Patients

Authors

  • Shalabh Jauhari , Shatakshi Rai , Reenoo Jauhari

DOI:

https://doi.org/10.47750/pnr.2023.14.S03.07

Abstract

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The classical classification of diabetes as proposed by the American Diabetes Association (ADA) in 1997 as type 1, type 2, other types, and gestational diabetes mellitus (GDM) is still the most accepted classification and adopted by ADA. Type 1 Diabetes Mellitus is a result of impaired insulin secretion, Type 2 Generally, a Negative feedback mechanism is there that controls homeostasis of our body, but there is no negative feedback mechanism for the reabsorption of glucose from the proximal renal tubule. Sodium–glucose cotransporter-2 (SGLT2) inhibitors are the drugs that control the reabsorption of glucose from the proximal renal tubule. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). There is an activation of sympathetic nervous system which causes the development of hypertension in type 2 diabetes mellitus (T2DM) patients. In this review we will discuss about various cardiovascular protection done by SGLT2 Inhibitors in both diabetic and non-diabetic patients.

Downloads

Published

2023-07-28 — Updated on 2023-07-28

Issue

Section

Articles

How to Cite

Effect Of Sglt2 Inhibitors On Hypretension, In Diabetic And Non-Diabetic Patients. (2023). Journal of Pharmaceutical Negative Results, 76-80. https://doi.org/10.47750/pnr.2023.14.S03.07